ArticleJournal of medical primatology2015
The use of glucocorticoids in marmoset wasting syndrome.
Article in Journal of medical primatology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 29 citations in OpenAlex.
- Validation of Body Condition Scoring as a Screening Test for Low Body Condition and Obesity in Common Marmosets (Callithrix jacchus).American journal of primatology · 2025Article
- Recent Advances in the Etiology, Diagnosis, and Treatment of Marmoset Wasting Syndrome.Veterinary sciences · 2025Review
- Prevalence of major diseases in common marmosets (Frontiers in veterinary science · 2025Article
- Review of Environmental and Health Factors Impacting Captive Common Marmoset Welfare in the Biomedical Research Setting.Veterinary sciences · 2023Review
- Association of Primate Veterinarians Guidelines for the Management of Diarrhea.Journal of the American Association for Laboratory Animal Science : JAALAS · 2023Article
- The Common Marmoset-Biomedical Research Animal Model Applications and Common Spontaneous Diseases.Toxicologic pathology · 2022Article
- Analysis of gut microbiome profiles in common marmosets (Callithrix jacchus) in health and intestinal disease.Scientific reports · 2022Article
- Immunohistochemical Characterization of a Duodenal Adenocarcinoma with Pulmonary, Hepatic and Parapatellar Metastases in a Common Marmoset (Callithrixjacchus).Journal of comparative pathology · 2021Article
- Changes in the faecal microbiome of pied tamarins (Saguinus bicolor) associated with chronic, recurrent diarrhoea and weight loss.Animal microbiome · 2021Article
- Clinical Management of Gastrointestinal Disease in the Common Marmoset (Callithrix jacchus).ILAR journal · 2020Review
- Novel gastrointestinal disease in common marmosets characterised by duodenal dilation: a clinical and pathological study.Scientific reports · 2020Article
- Article
- Measurement of the α1-proteinase inhibitor (α1-antitrypsin) of common marmoset and intestinal protein loss in wasting syndrome.Bioscience reports · 2019Article
- Fecal Concentrations of N-methylhistamine in Common Marmosets (Comparative medicine · 2019Article
- Colonic inflammation affects myenteric alpha-synuclein in nonhuman primates.Journal of inflammation research · 2019Article
- Tranexamic Acid and Supportive Measures to Treat Wasting Marmoset Syndrome.Comparative medicine · 2016Article
- Serum matrix metalloproteinase 9 (MMP9) as a biochemical marker for wasting marmoset syndrome.The Journal of veterinary medical science · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMarmoset wasting syndrome (MWS) is one of the leading causes of morbidity and mortality in captive marmosets, and thus far no reliable treatment has been found. Glucocorticoids are used widely to treat inflammatory conditions of the GI tract such as human and feline inflammatory bowel disease, which, such as MWS, are histologically characterized by chronic lymphoplasmacytic inflammation in the intestines. Budesonide is a glucocorticoid with few reported side effects due to the majority of it being metabolized into inactive compounds by the liver before entering the systemic circulation.
methodEleven marmosets presented with antemortem signs consistent with MWS and were treated with oral prednisone or budesonide for 8 weeks.
resultsThe marmosets in our study demonstrated a significant increase in both weight and albumin levels (relative to pre-treatment values) after glucocorticoid therapy.
conclusionsGlucocorticoids are an effective therapy to ameliorate the clinical signs associated with MWS with minimal side effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.